Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Rhabdomyosarcoma
•
Pediatric Oncology
•
Oncology
Which oral chemotherapy regimen do you use in relapsed fusion positive rhabdomyosarcoma?
Related Questions
What is your approach to patients/parents seeking alternative or complementary treatment in pediatric oncology patients?
How do you approach revaccination after chemotherapy, and what labs (if any) do you use to assess immune reconstitution?
What are the main barriers you encounter in enrolling pediatric oncology patients on clinical trials?
How would you manage moderate eosinophilia (~2-3k) with no evidence of end organ damage?
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?
If a pediatric patient has a prior history of cancer-associated thrombosis while receiving active treatment, can they be on estrogen-containing OCPs in the future?
What role do genetic and molecular profiling play in predicting which patients with high-risk localized RMS benefit from maintenance chemotherapy with vinorelbine and low-dose cyclophosphamide?
What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?
How will you treat an uterine embryonal rhabdomyosarcoma with regional node involvement resected to involved parametrial margins?
How would you manage a rare presentation of an older adult after gross total resection of an "infant-type hemispheric glioma" of the left frontal lobe, IDH1 negative and negative for MYB fusions?
